Medicinal Use Of Cannabis. Dr Ben Jansen Burleigh Heads Cannabis FRNZCGP FRACGP FRCUCP
|
|
- Patrick Evans
- 5 years ago
- Views:
Transcription
1 Medicinal Use Of Cannabis Dr Ben Jansen Burleigh Heads Cannabis FRNZCGP FRACGP FRCUCP
2 Medicinal Use Of Cannabis
3 BurleighHeadsCannabis.com
4 Take Home Messages No direct mortality from cannabis use, ever. Medicinal Cannabis does not need to get the patient high CBD, among other cannabinoids, modulate THC effects Start low and titrate dose to effect: THC 1mg, CBD 5mg BD PO Monitor co-administered drug levels or end organ function if required The non-psychoactive oral natural raw acid forms of the cannabinoids are being used for CB2 reception modulation and preventing oxidative stress (among other effects)
5 Historical Medicinal Use Of Cannabis
6 Historical Medicinal Use Of Cannabis
7 Public Opinion On Regulation? Prohibition Medication Restricted Medication Open Recreational Use* (still requires a level of quality and control for sale)
8 CAMH Cannabis Policy Framework, Oct 2014
9 CAMH Cannabis Policy Framework, Oct 2014
10 Predicted Worldwide Legal Cannabis Spending
11 PubMed search 2017/4/ results for Cannabis, or Marijuana, or THC, or CBD Compared to for Paracetamol, or Acetaminophen Compared to 7511 for Metoprolol Compared to 2598 for Ramipril
12 PubMed search 2018/4/ results for Cannabis, or Marijuana, or THC, or CBD Compared to for Paracetamol, or Acetaminophen Compared to 7724 for Metoprolol Compared to 2652 for Ramipril
13 Mortality
14 Mortality Opioid deaths estimated Worldwide in 2014 by the WHO deaths from Opioid Pain Relievers in the USA National Center on Health Statistics, CDC WONDER 56,000 emergency room visits and 26,000 hospitalizations yearly from Paracetamol, and 458 deaths in the USA. Nourjah P et al. Pharmacoepidemiol Drug Saf Jun;15(6): ,200 deaths annually as a result of NSAID-induced GI bleeding in the USA. Tarone RE et al. Am J Ther. 2004;11(1): Zero deaths from Cannabis, ever! Dr Lester Grinspoon MD, Professor Emeritus, Harvard Medical School.
15 Mortality Bachhuber et al, 2014 Medical Cannabis Laws And Opioid Overdose Mortality In The USA, States with medicinal cannabis had a 24.8% lower mean annual opioid overdose mortality rate (95% CI, -37.5% to -9.5%)
16 Endocannabinoid System
17 Endocannabinoid System The Bodies Own Cannabinoid System Named because it was unknown until the effects of THC were being investigated Mostly cell membrane G protein-coupled receptors Related to homeostasis, memory, immune function,.
18 Endocannabinoid System ECS homeostatic roles have been summarized as relax, eat, sleep, forget, and protect.
19 Endocannabinoid System
20 Endocannabinoid System Receptors
21 Endocannabinoid System CB1 receptors
22 Endocannabinoid System CB2 receptors The other main endocannabinoid is 2- Arachidonoylglycerol (2-AG) which is active at both cannabinoid receptors, along with its own mimetic phytocannabinoid, CBD 2-AG and CBD are involved in the regulation of appetite, immune system functions, pain management, and homeostasis
23 Endocannabinoid System Endogenous ECs Reggio PH. Endocannabinoid Binding to the Cannabinoid Receptors: What Is Known and What Remains Unknown. Current medicinal chemistry. 2010;17(14):
24 Endocannabinoid System - Anandamide Named from the Sanskrit word ananda meaning supreme joy (Devane et al 1992) Binds to CB1, CB2, GPR55, GPR119, GPR18, TRPV1 Abundant hippocampus endocannabinoid Produced on demand from ethanolamide addition to arachidonic acid (no vesicle storage)
25 Endocannabinoid System - Anandamide
26 Endocannabinoid System - 2-AG 2-arachidonoyl glycerol described first in 1995 Full agonist at CB1 and CB2. Does not bind TRPV1 The most abundant endocannabinoid Found in human breast milk
27 Endocannabinoid System 2-AG
28 TRPV1 receptor Aka Capsaicin receptor & the Vanilloid receptor 1 (Transient receptor potential cation channel subfamily V member 1) Involved in heat sensation and pain detection, and also regulation of body temperature Agonists possibly cause down regulation eg Capsaicin cream Cannabidiol is an agonist
29 Paracetamol and the EC system Paracetamol (or acetaminophen for the yanks in the audience) is a COX-2 inhibitor, but also Paracetamol is metabolically combined with arachidonic acid by FAAH to form AM404 (Narachidonoylaminophenol):
30 Paracetamol and the EC system AM404 a potent agonist at the TRPV1 vanilloid receptor, a weak agonist at both CB1 and CB2 receptors, and an inhibitor of anandamide reuptake As a result, anandamide levels in the body and brain are elevated In this fashion, paracetamol acts as a pro-drug for an endocannabinoid metabolite
31 Endocannabinoid System
32 CEDS Clinical Endocannabinoid Def Syn ECS homeostatic roles have been summarized as relax, eat, sleep, forget, and protect. Suboptimal ECS functioning considerations: migraine, fibromyalgia, irritable bowel syndrome, failure to thrive syndrome, depressive illnesses, uncompensated schizophrenia, multiple sclerosis, Huntington's, uncompensated Parkinson's, uncompensated anorexia, and chronic motion sickness. Correcting CEDS may be accomplished via at least three molecular mechanisms: 1. Augmenting Endocannabinoid ligand biosynthesis; 2. Decreasing Endocannabinoid ligand degradation; 3. Augmenting or increasing receptor density or function. McPartland JM, Guy GW, Di Marzo V. Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. Romanovsky AA, ed. PLoS ONE. 2014;9(3):e doi: /journal.pone
33 Cannabis Components 400+ molecules in raw Cannabis 100+ Terpenes (volatile unsaturated hydrocarbons found in the essential oils) 112+ different Cannabinoids Cannabinoids in acid forms Fibre PUFA s, phytosterols, vit E, G+C Linoleic Acid, omega 3 s + 6 s, folate, Mg, Fe, Zn, Protein
34 Hemp Seeds
35 Hemp Seeds
36 Phytocannabinoids CBG (Cannabigerol) CBC (Cannabichromene) CBL (Cannabicyclol) CBV (Cannabivarin) THCV (Tetrahydrocannabivarin) CBDV (Cannabidivarin) CBCV (Cannabichromevarin) CBGV (Cannabigerovarin) CBGM (Cannabigerol Monomethyl Ether) THC (Tetrahydrocannabinol) THCA (Tetrahydrocannbinolic acid) CBD (Cannabidiol) CBDA (Cannabidiolic Acid)
37 Cannabinoid Biosynthesis
38 Cannabinoid Biosynthesis
39 Cannabinoid Biosynthesis
40 CBD won t get a patient high CBD is not psychoactive (It s the THC that can have effects on the brain)
41 Cannabidiol CBD (key slide to remember) No high ; Not Psychoactive Side effects in high dose > cotton mouth, P450 inhibition, inhibit anti-epileptic medication metabolism,?drug interactions Low binding affinity for CB1 and CB2 receptors, but activates several non-cannabinoid receptors and ion channels, and... Delays the reuptake and breakdown of endogenous endocannabinoids (such as anandamide or 2AG) this is the entourage effect with other cannabinoids.
42 Cytochrome P450 Enzyme Interactions CYP450 enzymes are primarily located in the liver CYP450 enzymes production and breakdown organic molecules, especially some drugs In vitro interactions are minimal
43 CBD effects 5-HT1A serotonin receptor agonist with antidepressant activity (CBDa more of an agonist) TRPV1 agonist, with analgesic effects GPR55 antagonist, with anti-osteoporosis and anticancer cell proliferation effects CBD's anti-inflammatory and anti-anxiety effects are in part attributable to its inhibition of adenosine reuptake. A1A and A2A adenosine receptors play significant roles in cardiovascular function, regulating myocardial oxygen consumption and coronary blood flow. These receptors have broad antiinflammatory effects throughout the body
44
45 CBD Effects - S. Pisanti et al. (Pharmacology & Therapeutics, 2017)
46 CBD Myocardial Protection Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Durst et al. Am J of Physiology - Heart and Circ Physiology, 1 Dec 2007; 293 (6), H3602-H3607. DOI: /ajpheart The LAD coronary artery was transiently ligated for 30 min, and the rats were treated for 7 days with CBD (5 mg/kg ip) or placebo vehicle. Infarct size was reduced by 66% in CBD-treated animals.
47 Walsh et al Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion
48 CBD Neuroprotection - US Patent US US Patent US CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTANTS (2003) Assignee: The United States of America as represented by the Department of Health and Human Services, Washington, DC (US) This new found property makes Cannabinoids useful in the treatment and prophylaxis of a wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The Cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer s disease, Parkinson s disease and HIV dementia.
49 CBD Neuroprotection - US Patent US US Patent US CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTANTS (2003) Assignee: The United States of America as represented by the Department of Health and Human Services, Washington, DC (US) Example 7 The middle cerebral artery of chloral hydrate anaesthetised rats was occluded by insertion of suture thread into it. The animals were allowed to recover from the anesthetic and move freely for a period of two hours. After this time the suture was removed under mild anesthetic and the animals allowed to recover for 48 hours. Infarct size was approximately halved in the animals treated with cannabidiol, which was also accompanied by a substantial improvement in the neurological status of the animal.
50 CBD Neuroprotection - US Patent US US Patent US CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTANTS (2003) Assignee: The United States of America as represented by the Department of Health and Human Services, Washington, DC (US) Non-psychoactive Cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive Cannabinoids at high doses.
51 2015 England et al - Cannabinoids and stroke: a systematic review
52 Sharf Translating Endocannabinoid Biology into Clinical Practice - Cannabidiol for Stroke Prevention
53 Chagas et al (2014) - Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial (RCT, n=21) Double-blind RCT of placebo, Cannabidiol (CBD) 75 mg/day or CBD 300 mg/day. Groups treated with placebo and CBD 300 mg/day had significantly different mean total scores in the PDQ-39 (wellbeing and quality of life) (p = 0.05).
54 Leweke et al (2012) - Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (RCT, n=42) Double-blind RCT of Cannabidiol vs Amisulpride (a potent antipsychotic). Either treatment was safe and led to significant clinical improvement, but Cannabidiol displayed a markedly superior side-effect profile. Acutely psychotic patients age 18 to 50 years with a total Brief Psychiatric Rating Scale (BPRS) score 36 and a BPRS THOT factor (thought disorders) score 12. Patients were randomized (1:1) to receive either Cannabidiol or Amisulpride starting with 200 mg per day each and increased stepwise by 200 mg per day to a daily dose of 200 mg four times daily (total 800 mg per day) each within the first week. A dose reduction to 600mg per was allowed after week 2 if side effects.
55 Leweke et al (2012) - Cannabidiol enhances anandamide signalling and alleviates psychotic symptoms of schizophrenia (RCT, n=42)
56 Leweke et al (2012) - Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (RCT, n=42)
57 McGuire et al (2017) - Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial (n = 88) 1000mg/day vs placebo for 6weeks, RCT, n=88 On 4+weeks stable antipsychotic dose, and partial response to antipsychotic medication
58 McGuire et al (2017) - Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial (n = 88)
59 2011 Bergamashi et al - Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients (RCT, n=36)
60 2015 Blessing et al - Cannabidiol as a Potential Treatment for Anxiety Disorders
61 2018 Crombie et al - Psychobiological Responses to Aerobic Exercise in Individuals With Posttraumatic Stress Disorder (Blunted ECS in PTSD patients)
62 Englund et al, Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment (RCT, n=48)
63 Trial of CBD for Drug-Resistant Seizures in Dravet Syndrome, 2017 NEJM N=120, RCT
64 Ayurveda text (5000yrs BCE) and Sir. William Brooke O'Shaughnessy (1800 s) already knew Cannabis worked for seizure disorders On the preparations of the Indian hemp, or gunjah (Cannabis Indica), their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive disorders (O Shaghnessy 1843)
65 Gigli et al, Cannabidiol (CBD) restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells 24 h Time course: TEER (Transepithelial Electrical Resistance) changes following treatment with CBD (Cannabidiol)
66
67 Understanding CBD (Patient reports on use,california) Hello MD/Brightfield Group 2017
68 CBD Dose To decrease THC neurological effects: 1:1+ THC<CBD ratio Start 5mg BD Chronic pain: mg CBD by mouth for an average of 25 days Anxiety: mg CBD by mouth for four weeks Epilepsy: mg of CBD by mouth daily for up to 4.5 months Movement problems associated with Huntington s disease: 10 mg per kilogram of CBD by mouth daily for six weeks Sleep disorders: mg CBD by mouth Multiple Sclerosis symptoms: Cannabis plant extracts containing mg of a THC-CBD combination by mouth daily for 2-15 weeks Schizophrenia: 40-1,280 mg CBD by mouth daily for up to four weeks
69 CBD Bioavailability Oral 10% > 20% with long-chain TG Inhalation 30% Zgair A, Wong JC, Lee JB, et al. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American Journal of Translational Research. 2016;8(8):
70 WHO Expert Committee on Drug Dependence, Nov 2017 In humans, CBD exhibits no effects indicative of any abuse or dependence potential. CBD has been demonstrated as an effective treatment of epilepsy in several clinical trials, with one pure CBD product (Epidiolex ) currently in Phase III trials. There is also preliminary evidence that CBD may be a useful treatment for a number of other medical conditions. Across a number of controlled and open label trials CBD of the potential therapeutic effects of CBD it is generally well tolerated, with a good safety profile.
71
72 Tetrahydrocannabinolic acid - THCA No high ; Not Psychoactive Weak CB1 and CB2 binding. Inhibitor of PC-PLC, COX-1, COX-2, TRPM8, TRPV1, FAAH, NAAA, MGL, and DGLα, and an inhibitor of anandamide transport, as well as an agonist of TRPA1 and TRPV2. Analgesic Relieves pain, Cox-2 Inhibition. Anti-Emetic Reduces vomiting and nausea. Anti-Inflammatory Especially GI inflammation. Anti-Proliferative Inhibits cancer cell growth, TNF inhibition Modulates Immune System THCa has been shown to both improve and potentially suppress the immune system functions. Neuroprotective in cellular and animal models.
73 Cannabis Juicers - Raw Acid Cannabinoids Dr. Courtney has researched the benefits of raw cannabis and has come to the following conclusions: Smoking cannabis may not treat the disease, only the symptoms Therapeutic levels of cannabinoids are better achieved through ingestion When cannabis is heated or burned, the chemical structure of the plant compounds are changed, specifically the acidity of THC, which alters its ability to be therapeutic Raw cannabis activates the brain s cannabinoid system, which triggers an antioxidant release These antioxidants act as a cleaner and remove damaged cells from the body Raw cannabis improves the efficiency of the cells in our body Creating oils, butters or eating the raw plant is the best way to get the necessary beneficial compounds Dr Courtney s wife successfully treats her lupus with raw cannabis
74 Cannabis Juicers Juicing specifically takes a lot of material; Dr. Courtney suggests big shade leaves or 2-3 raw buds (2-3 inches in length) per day for therapeutic benefits Added to salads or sprinkled on foods Keep below 100*c to remain non-psychoactive GI anti-inflammatory, higher antioxidants
75 THC
76 Δ9-Tetrahydrocannabinol THC THCa is not psychoactive (no high) > but heated to 120*c will turn into THC which is psychoactive LD50 could not be determined in either rhesus monkeys or dogs, as single oral doses of up to 9000 mg/kg of either delta-8- or delta-9-thc in dogs or monkeys were non-lethal (Compare to Nicotine: for rats 50 mg/kg, for humans mg/kg) Thompson, G. R. et. al., Toxicol. Appl. Pharmacol. 25: The LD50 values for Fischer rats treated orally with single doses of delta-9-thc and delta-8thc, and observed for 7 days, are 1910 mg/kg and 1980mg/kg (for males) respectively and 860 mg/kg (for females)
77 Δ9-Tetrahydrocannabinol - THC THC is a partial agonist at CB1 > CB2 receptors THC binding to CB1 pathways acts as a downregulator of those neurons THC may act on some areas to increase endogenous endocannabinoid activity Pertwee RG. Brit J of Phar, (2): THC is positive allosteric modulator of the μ- and δ-opioid receptors Kathmann M et al. Naunyn Schmiedebergs Arch. Pharmacol, (5):
78 THC Effects Analgesic Relieves pain Anti-Emetic Reduces vomiting and nausea Anti-Proliferative Inhibits cancer cell growth Antioxidant Prevents the damage of oxidatio to other molecules in the body Antispasmodic Suppresses muscle spasms Anxiolytic While not fully recognized as an anxiolitic compound THC does seem to assist in the anxiety associated with PTSD Appetite Stimulant Δ9-THC is the only cannabinoid identified that is an appetite stimulant, giving people the stereotypical munchies many users describe Euphoriant Produces feelings of euphoria, promotes happiness and relaxation Neuroprotective
79 THC Metabolism
80 THC Metabolism
81 Distribution of THC in the body (Prof Nahas 1975)
82 Cytochrome P450 Enzyme Interactions CYP450 enzymes are primarily located in the liver CYP450 enzymes production and breakdown organic molecules, especially some drugs In vitro interactions are minimal
83 Cytochrome P450 Enzyme Interactions In clinical trials where Sativex has been taken concomitantly with other drugs metabolised by the CYP450 enzyme system, no clinically apparent drug-drug interactions have been seen at clinical doses. The inhibitory effects of Sativex on the CYP450 system seen in vitro and in animal models were only seen at exposures significantly higher doses than the maximal observed in clinical trials.
84 Cytochrome P450 Enzyme Interactions* There is genetic variation in P450 metabolism, and thus metabolism of cannabinoids THC and CBD inhibit some P450 enzymes, while smoking cannabis can induce P450 1A2 Thus, if taking a medication that needs to have levels monitored, and there is addition/removal/change of dose of cannabinoids, then testing should occur
85 Drug Interactions - THC Besides possible P450 interactions, pharmacodynamic interactions should be expected between THC and: - drugs with sympathomimetic activity (tachycardia, hypertension) - central nervous system depressants (drowsiness, ataxia) - drugs with anticholinergic effects (tachycardia, drowsiness)
86 THC dosing titration to effect Inhaled (vapourised) THC has immediate effects that the patient can titrate, with maximal effects at 4 minutes, and terminal effects ended by 4 hours 1-2mg THC inhaled is a good starting dose, with pharmacist consideration on the strength of the cannabis or THC resin 0.1g cannabis or a less than a quarter of a SMALL would be a relatively equivalent visible amount
87 THC dosing titration to effect
88 THC dosing titration to effect Oral use is slower to titrate; start with 2.5mg THC, a dose factor of 2.5 increase over inhalation Oral effects are variable from 30mins to 60mins, and lasting 4 to 8 hours generally, in a dose dependant manner First dosing should be in a safe familiar location in case of adverse emotional feelings, consider stat benzodiazepine PRN
89 THC Contraindications Unstable or severe cardiovascular disease Hypotension as Cannabis will lower blood pressure Psychotic illness or a risk of psychotic illness remember to screen with PQ-16 Screening Test (Prodromal Questionaire) Addiction risk factors History of Cannabis abuse
90 THC adverse effects Dose dependant* Red conjunctiva Increased hunger Euphoria Impaired short term memory Sedation and impaired cognitive function Anxiety, paranoia, thought disorder
91 THC adverse effects - Cannabinoids in the management of difficult to treat pain, Russo 2008
92 THC adverse effects High dose can lead to intoxication and thus: Extreme sleepiness/sedation Cognitive deficits Depersonalisation Hallucinations/illusion Toxic psychosis generally lasting hours but occasionally as long as a week (Radhakrishnan et al. Gone to pot A review of the association between cannabis and psychosis. Frontiers in Psychiatry, (54). doi: /fpsyt )
93 THC adverse effects Meier et al 2016 (Dunedin longitudinal study) Cannabis joint-years from ages 26 to 38 years was associated with poorer periodontal health at age 38 years. However, cannabis use was unrelated to other physical health problems. Unlike cannabis use, tobacco use was associated with worse lung function, systemic inflammation, and metabolic health at age 38 years, as well as within-individual decline in health from ages 26 to 38 years.
94 Degenhardt et al (2003) - Testing hypotheses about the relationship between cannabis use and psychosis There was a steep rise in the prevalence of cannabis use in Australia over the past 30 years and a corresponding decrease in the age of initiation of cannabis use. There was no evidence of a significant increase in the incidence of schizophrenia over the past 30 years.
95 Degenhardt et al (2003) - Testing hypotheses about the relationship between cannabis use and psychosis Conclusions: Cannabis use does not appear to be causally related to the incidence of schizophrenia, but its use may precipitate disorders in persons who are vulnerable to developing psychosis and worsen the course of the disorder among those who have already developed it.
96 Morgan et al (2016) - AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers Variation at the rs locus of the AKT1 gene predicted acute psychotic response to cannabis along with dependence on the drug and baseline schizotypal symptoms
97
98 Wang et al, Adverse effects of medical cannabinoids: a systematic review (THC) 23 randomized controlled trials and 8 observational studies of medicinal cannabis 96.6% of side effects were not serious Of the 164 serious adverse events, the most common was relapse of multiple sclerosis (12.8%), vomiting (9.8%) and urinary tract infection (9.1%). The rate of non-serious adverse events was higher among participants assigned to medical cannabinoids than among controls (RR 1.86, % CI) The rates of serious adverse events did not differ significantly between these 2 groups (RR 1.04, % CI). Dizziness was the most commonly reported non-serious adverse event (15.5%) among people exposed to cannabinoids.
99 Allan and Ton, Harms of Medical Cannabinoids: Up In Smoke! (Alberta College of Family Physicians) (THC) 11 systemic reviews (THC + Synthetics vs placebo) Adverse Events: NNH = 5-8 Stopped due to AE: NNH = 8-22 Adverse Effects Sedation NNH = 5, Feeling High NNH=2-4, Euphoria NNH=9, Dizziness NNH=5, Visual blurring/hallucination NNH=3, Hypotension NNH=8, Disorientation NNH=15, Hallucination NNH=17, Paranoia NNH=20 Adverse event rates varied significantly between nabiximol, nabilone, dronaninol, inhaled marijuana NNH=4-7 Regular users report less side effects
100 2016 Department of Health (WA) - Pain Health
101 Improved control and decreased access of cannabis to youth after legalisation measures Colorado and Washington States 2014 legalisation
102 Braga et al, Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder N=200 Those with Cannabis Use Disorder (CUD ) and Bipolar 1 had better neurocognitive performance
103 2017 Gruber et al - The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment (n=41) Following 3 months of treatment, MMJ patients demonstrated improved task performance accompanied by changes in brain activation patterns. Interestingly, after MMJ treatment, brain activation patterns appeared more similar to those exhibited by healthy controls from previous studies than at pretreatment, suggestive of a potential normalization of brain function relative to baseline
104 Cannabis effects on driving lateral control with and without alcohol Hartman et al, 2015
105 THC Therapeutic Evidence
106
107 Richards et al, 2012 (Cochrane Review) Neuromodulators for pain management in rheumatoid arthritis Oromucosal cannabis vs placebo: small, significant difference favouring cannabis in the verbal rating score 'pain at present' (MD -0.72, 95% CI to -0.13) after five weeks. (n=58)
108 Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer Schleider et al, 2018 (n=2970) > Pain intensity:
109 Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer Schleider et al, 2018 (n=2970) > QOL assessment:
110 Pharmacological management of chronic neuropathic pain (2014): revised consensus statement from the Canadian Pain Society
111 Grant, Medicinal Cannabis and Painful Sensory Neuropathy NNT to achieve a 30% reduction in pain n=78, RCTs
112 Bradford, 2015 Medical Marijuana Laws Reduce Rx Medication Use In Medicare (Per Physician Per Year!)
113 Corroon et al, 2017 Cannabis as a substitute for prescription drugs a cross-sectional study
114 2017 GW Pharma Phase 2 THC + CBD for Recurrent Gliobastoma Multiforme
115 Naftali et al, Treatment of Crohn's disease with cannabis: an observational study Fifteen of the patients had 19 surgeries during an average period of 9 years before cannabis use, but only 2 required surgery during an average period of 3 years of cannabis use
116 Carley et al Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea (RCT) Each phase is 73 adults with moderate or severe OSA received either placebo (N = 25), 2.5 mg dronabinol (N = 21), or 10 mg dronabinol (N = 27) daily, 1 hour before bedtime for up to 6 weeks.
117 Rhyne et al, Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population N=121, retrospective study Migraine headache frequency on average decreased from 10.4 to 4.6 headaches per month with cannabis medication use Vapourised or smoked cannabis use by some patients to abort migraines.
118 Duran et al, Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting N=16, RCT 5/7 (71.4%) experienced a complete response with cannabinoid medicine vs. 2/9 (22.2%) with placebo. The incidence of AEs was higher in the CBM group (86% vs. 67%).
119 Smith et al, 2015 (Cochrane Database) - Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 23 RCTs, cannabis-based medication with either placebo or with a conventional anti-emetic in adults Vs Placebo complete absence of vomiting RR 5.7; 95% CI 2.6 to 12.6 Vs Prochlorperazine equivalence or better no nausea (5 trials; 258 participants; RR 1.5; 95% CI 0.67 to 3.2) no vomiting (4 trials; 209 participants; RR 1.11; 95% CI 0.86 to 1.44) complete absence of nausea and vomiting (4 trials; 414 participants; RR 2.0; 95% CI 0.74 to 5.4) preference for cannabinoids (7 trials; 695 participants; RR 3.3; 95% CI 2.2 to 4.8) Comparisons with metoclopramide, domperidone and chlorpromazine, there was weaker evidence, based on fewer trials and participants
120 Adejumo et al, Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease N=319,514. Analysis of 2014 Healthcare Cost and Utilization Project - Nationwide Inpatient Sample (NIS) discharge records of patients 18years and older, who had a past or current history of abusive alcohol use. Three cannabis exposure groups: non-cannabis-users (90.39%), non-dependentcannabis-users (8.26%) and dependent cannabis users (1.36%). Cannabis users (dependent and non-dependent cannabis use) showed significantly lower odds of developing: alcoholic steatosis = AOR: 0.55 ( ), steatohepatitis = 0.57 ( ), fibrosis/cirrhosis = 0.45 ( ) and hepatocellular carcinoma 0.62 ( ). Further, dependent users had significantly lower odds than non-dependent users for developing liver disease
121 Lotan et al, Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study Unified Parkinson Disease Rating Scale score improved significantly from 33.1 (13.8) at baseline to 23.2 (10.5) after cannabis consumption (t = 5.9; P < 0.001). Analysis of specific motor symptoms revealed significant improvement after treatment in - tremor (P < 0.001) - rigidity (P = 0.004) - bradykinesia (P < 0.001)
122 Cannabis Products
123 Cannabis Devices
124 Cannabis Devices
125 Cannabis Devices
126 Further Information
127 Sativex THC 2.7mg/CBD 2.5mg per spray In alcohol and peppermint oil Oromucosal (mouth) spray Traces of terpenes and other cannabinoids Licensed for spasms in MS P.I./Datasheet available online Plasma peak 1-2hrs Start with 1 spray at night Increase by 1 spray per day BD dosing with more at night
128 Cannabis Prescription Patient screening, education and consent THC:CBD ratio product selection Government application Rx: CBD > THC/CBD - CBD 5mg BD PO - THC 1mg dose vape/2.5mg oral - Titrate both gradually to effect Monitor, Review, Report
129
130 Take Home Messages No direct mortality from cannabis use, ever. Medicinal Cannabis does not need to get the patient high CBD, among other cannabinoids, modulate THC effects Start low and titrate dose to effect: THC 1mg, CBD 5mg BD PO Monitor co-administered drug levels or end organ function if required The non-psychoactive oral natural raw acid forms of the cannabinoids are being used for CB2 reception modulation and preventing oxidative stress (among other effects)
Cannabis. Member of the Cannabaceae family of flowering plants (along with hops) Cannabis sativa (v. sativa, indica, afghanica, ruderalis)
Member of the Cannabaceae family of flowering plants (along with hops) sativa (v. sativa, indica, afghanica, ruderalis) Only females flowers contain high concentrations of psychoactive oils (cannabinoids)
More informationMedicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer
Medicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer Medicinal cannabis Substantial public interest Legalised by the Qld Government Guidance
More informationMedical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center. Disclosure.
Medical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center Controversies in Pain Management Conference Johnson City, TN November 13, 2015 Disclosure
More informationCannabidiol as a potential treatment for anxiety disorders. Esther Blessing, MD PhD
Cannabidiol as a potential treatment for anxiety disorders Esther Blessing, MD PhD Overview History and of cannabidiol (CBD) and cannabis Safety and tolerability of CBD CBD pharmacology Clinical need for
More informationMedical Marijuana for Pain How Does Cannabis Work on Your Body?
Medical Marijuana for Pain How Does Cannabis Work on Your Body? Jeremy Spiegel, MD Medical Director - Casco Bay Medical Westbury, Long Island, New York Intro Brief History of Cannabis Physiology of Cannabis
More informationThe Scientific Side of Medical Marijuana
The Scientific Side of Medical Marijuana Ken Mackie, MD Indiana University Bloomington, IN December 3, 2009 kmackie@indiana.edu Financial disclosures NIH (NIDA) - research grants Alzheimer s Association
More informationResearch on Cannabis and PD: Is there any evidence?
Research on Cannabis and PD: Is there any evidence? Benzi M. Kluger, MD, MS Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver DISCLOSURES
More informationWeeding out the myths on Medical Cannabis
Weeding out the myths on Medical Cannabis Presented by A/Prof David Allsop Lambert Initiative for Cannabinoid Therapeutics University of Sydney For Walk on the Wild Side 2016: Superstition or Evidence?
More informationThe Effects known & unknown of Marijuana in Older Adults. Danielle Fixen, PharmD, BCGP, BCPS University of Colorado School of Pharmacy
The Effects known & unknown of Marijuana in Older Adults Danielle Fixen, PharmD, BCGP, BCPS University of Colorado School of Pharmacy Learning Objectives 1. Review various dosing strategies for medical
More informationCurious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD
Curious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD Speaker Disclosures We have/had no financial relationships with any commercial interests
More informationTHE COMPLETE CBD GUIDE
THE COMPLETE CBD GUIDE WHAT IS CBD (CANNABIDIOL)? 2 WHERE DOES CBD COME FROM? 3 HOW DOES CBD WORK IN THE BODY? 4 HOW MUCH CBD DO I TAKE? 5-6 CBD OIL VS. HEMP OIL 7 CBD NOT THC 8 THE BENEFITS OF CBD 9 PETS
More informationMedicinal Marijuana: The Canadian Journey
Medicinal Marijuana: The Canadian Journey Nady el-guebaly MD Professor & Head, Addiction Division, UofC Research Director, Alberta Gambling Research Institute Chief Examiner, ISAM Certification Disclosures:
More informationCANNABIS FOR THE RHEUMATOLOGIST
CANNABIS FOR THE RHEUMATOLOGIST Dr Jagtar Singh Nijjar NIHR Clinical Lecturer in Rheumatology Disclosures None 1 Overview The history of cannabis use Anecdotal use of cannabis in chronic pain The biology
More informationMedical Marijuana A Primer for Pharmacists
Medical Marijuana A Primer for Pharmacists Emory S. Martin, PharmD FASHP Texas Society of Health System Pharmacists Learning Objectives Recognize key components of the endocannabinoid system Identify possible
More informationCannabinoids and Mental Health
Cannabinoids and Mental Health https://upload.wikimedia.org/wikipedia/commons Karen M. Lounsbury, PhD Professor of Pharmacology 802-656-3231, Karen.lounsbury@uvm.edu Objectives Describe the underlying
More informationJames McCormack BSc (Pharm), PharmD Professor Faculty of Pharmaceutical Sciences University of British Columbia Vancouver, BC, Canada
James McCormack BSc (Pharm), PharmD Professor Faculty of Pharmaceutical Sciences University of British Columbia Vancouver, BC, Canada My Agenda Discuss the best available evidence Put the evidence into
More informationCBD and Your Health.
CBD and Your Health. Cannabidiol (CBD) is a molecule found in plant species such as agricultural (or industrial) hemp, and Echinacea. CBD is one of at least 489 distinct compounds within hemp: it is clear
More informationCBD HOPE AND/OR HYPE?
CBD HOPE AND/OR HYPE? Gregor Zorn STCM 3.0 Confernce 19.1.2019 Bern, CH Cannabidiol (CBD) Isolated 1940 (Adams, 1940), Structure identified in 1963 (Mechoulam and Shvo, 1963) Major cannabinoid in hemp
More informationA look at Marijuana in 2014
A look at Marijuana in 2014 Paul Snyder MA., LADC Overview and Objectives Discuss the mental and physical effects of marijuana use Describe the criteria for Cannabis use disorder according to the DSM 5
More informationMedical Cannabis use in the Older Patient
Medical Cannabis use in the Older Patient Dr. Amanjot Sidhu Division of Geriatric Medicine McMaster University Audience Poll What is the fastest-growing demographic of cannabis users? a) Ages 14-23 b)
More informationSteven G. Kinsey, PhD Associate Professor, Department of Psychology West Virginia University
Steven G. Kinsey, PhD Associate Professor, Department of Psychology West Virginia University sgkinsey@mail.wvu.edu Any opinions expressed are my own and do not reflect any official position of WVU beanpot.co
More informationMedical Cannabis use in the Older Patient. Amanjot Sidhu, MD, FRCPC Division of Geriatric Medicine McMaster University
Medical Cannabis use in the Older Patient Amanjot Sidhu, MD, FRCPC Division of Geriatric Medicine McMaster University Disclosure Relationships with commercial interests: Grants/Research Support: none Speakers
More informationCANNABIS AND PAIN. Debra Kimless, M.D. Medical Director, ForwardGro MAOP Annual Meeting September 14, 2018
CANNABIS AND PAIN Debra Kimless, M.D. Medical Director, ForwardGro MAOP Annual Meeting September 14, 2018 FDA APPROVAL: PREGABALIN, DULOXETINE, MILNACIPRAN FOR FIBROMYALGIA PREGABALIN, DULOXETINE FOR
More informationFederal Law: Marijuana
Federal Law: Marijuana Marijuana is a Schedule I drug under Federal Controlled Substances Act Makes possession, usage, purchase, sale, and/or cultivation of marijuana illegal at the federal level May not
More informationCANNABIS LEGALIZATION: SUPPORT MATERIAL FOR MANITOBA PHYSICIANS
CANNABIS LEGALIZATION: SUPPORT MATERIAL FOR MANITOBA PHYSICIANS 1. GENERAL INFORMATION Cannabis 101 What is cannabis? Cannabis is a product derived from the Cannabis sativa plant. Cannabis contains hundreds
More informationWHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis. Expert Peer Review 2
WHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis Expert Peer Review 2 1. Comments based on the review report a. Evidence on dependence and abuse potential Extracts
More informationCannabidiol, or CBD, Benefits for Pain, Mental Illness & Anxiety
Cannabidiol, or CBD, Benefits for Pain, Mental Illness & Anxiety The use of medical marijuana continues to be an emotionally and politically charged issue. Although cannabis oil preparations have been
More informationDr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina) S. Korownyk EDMONTON AB MEDICAL CANNABANOIDS IN PRIMARY CARE
Society of Rural Physicians of Canada 26TH ANNUAL RURAL AND REMOTE MEDICINE COURSE ST. JOHN'S NEWFOUNDLAND AND LABRADOR APRIL 12-14, 2018 262 Dr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina)
More informationMedical Marijuana. 1. is a plant species, variety known as hemp. 3. Tetrahydrocannabinol is an aromatic with low water solubility.
Medical Marijuana Questions from Part 1: 1. is a plant species, variety known as hemp. a. Cannabis sativa Linnaeus b. Cannabis sativa c. Cannabis indica d. Cannabis Lemark 2. The major psychoactive compound
More informationI would like to begin by acknowledging that we are on the ancestral grounds of the Beothuk people
I would like to begin by acknowledging that we are on the ancestral grounds of the Beothuk people Introduction to the Cannabinoid System And Medical Use Dr Alia Norman Radiation Oncologist Cannabinoid
More informationUse of Cannabinoids in Medical Practice
Use of Cannabinoids in Medical Practice Annual Scientific Assembly Family Medicine Review 2016 Murray Opdahl BSPE, MD, CCFP Objectives Briefly present: An overview of available cannabinoids Concerns voiced
More informationCannabinoids & Pain. the state of the art the state of the science. Insights from Academic and Industry leaders. Background on. Cannabinoids and Pain
WHTE PAPER Cannabinoids & Pain the state of the art the state of the science Insights from Academic and Industry leaders Background on Cannabinoids and Pain About the Cannabinoids and Pain 2012 Symposium
More informationHistory Of Medical Cannabis
History Of Medical Cannabis Historical and archaeological evidence of widespread use in ancient times as medicine, food, textiles & for sacraments, rituals Possibly first domesticated crop Introduction
More informationMedical Marijuana Update Chris Belletieri, DO
Dr. Belletieri has provided no disclosures. Graduated PCOM in 1996 In private practice since 1999 Board Certified in FP since 1999 Program Director of FP residency at Lower Bucks Hospital in Bristol, PA
More informationLearning Objectives 1/8/2019. Therapeutic Potential of the Marijuana-Derived Cannabinoids THC and CBD. Disclosures. Outline. Take home messages
Therapeutic Potential of the Marijuana-Derived Cannabinoids THC and CBD CECILIA HILLARD, PHD DEPARTMENT OF PHARMACOLOGY NEUROSCIENCE RESEARCH CENTER Disclosures Member of the Scientific Advisory Board
More informationCannabis in the treatment of Autism:
Cannabis in the treatment of Autism: Are we ready? Deb Karhson, PhD and Lawrence Fung, MD, PhD Cannabis Anecdotal Data: Comparing Epilepsy and Autism+ Science of Cannabinoids: Endocannabinoid System Receptor
More informationDr. Meldon Kahan. Women s College Hospital. with PIA LAW
with PIA LAW and Toronto ABI Network Dr. Meldon Kahan Women s College Hospital Dr. Meldon Kahan is an Associate Professor in the Department of Family Medicine at University of Toronto, and Medical Director
More informationPHYTOCANNABINOIDS AND THEIR MEDICINAL APPLICATIONS
Toll Free: 1.800.516.1504 info@vitaliset.com vitaliset.com Find us on Instagram! vitalisextractiontech PHYTOCANNABINOIDS AND THEIR MEDICINAL APPLICATIONS A recent history of prejudice against the cannabis
More informationCDHA 2016 Fall Symposium. Speaker Handout Files. For registered attendees only
CDHA 2016 Fall Symposium Speaker Handout Files For registered attendees only Providing Care in a Marijuana Legal World Heather Rogers, BSDH heatherrdh@heatherrdh.com Objectives We will discuss some of
More informationCannabis and the Endocannabinoid System
Cannabis and the Endocannabinoid System September 7, 2018 Bangkok, Thailand David Bearman, MD Goleta, California Executive VP, American Academy of Cannabinoid Medicine AACMSITE.org Shen Nung Ping
More informationCANNABINOIDS: NOVEL MOLECULES WITH SIGNIFICANT CLINICAL UTILITY
CANNABINOIDS: NOVEL MOLECULES WITH SIGNIFICANT CLINICAL UTILITY NOEL ROBERT WILLIAMS MD FACOG DIRECTOR OPTIMAL HEALTH ASSOCIATES OKLAHOMA CITY, OKLAHOMA How Did We Get Here? In November 2012 Tikun Olam,
More informationCANNABIDIOL (CBD) THE BE ALL END ALL?
CANNABIDIOL (CBD) THE BE ALL END ALL? John Schaeffer, DO PMG neurology specialists Clinical associate professor Department of neurology University of Washington school of medicine CANNABIS BRIEF HISTORY
More informationMedicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system
Medicinal cannabis What is medicinal cannabis? Broadly speaking, medicinal cannabis is cannabis prescribed to relieve the symptoms of a medical condition, such as epilepsy. It is important to make the
More informationPennsylvania House of Representatives. Joint Health and Judiciary Committee Hearing. Medical Cannabis - Health Care Forum
Pennsylvania House of Representatives Joint Health and Judiciary Committee Hearing Medical Cannabis - Health Care Forum Tuesday, March 24, 2015 Philadelphia, Pennsylvania Testimony offered by: David J.
More informationMedical Cannabis. Danial Schecter, MD, CCFP. Vocational Rehabilitation Association November 7th, Executive Director Cannabinoid Medical Clinic
Medical Cannabis Danial Schecter, MD, CCFP Executive Director Cannabinoid Medical Clinic Vocational Rehabilitation Association November 7th, 2014 Conflict of Interest This program has not received financial
More information(THC) Delta9-tetrahydrocannabinol:
(THC) Delta9-tetrahydrocannabinol: Most prominent compound found in the cannabis plant found in the 1960 s. THC binds to the CB1 and CB2 receptors causing a change in the function of the cell it is binding.
More informationADVANCED CLINICAL CANNABINOID PROVIDER EXAM ACCP
ADVANCED CLINICAL CANNABINOID PROVIDER EXAM ACCP Page 1 1. In what year did the possession and transfer of cannabis for recreational use become illegal in the United States? A. 1937 B. 1941 C. 1933 2.
More informationThe Endocannabinoid System
The Endocannabinoid System Think of this system as the wizard behind the curtain. It underlies all the other systems, including the Autonomic Nervous System. Overall it influences well-being and the perception
More informationMarijuana and Adolescents: Truth and Consequences. Disclosure Statement OBJECTIVES. Secondary Objectives. State of Marijuana in US
Marijuana and Adolescents: Truth and Consequences Clinical Advances in Pediatrics Symposium Children s Mercy Park September 28, 2017 Disclosure Statement I have no actual or potential conflict of interest
More informationObjectives. 1. Review controversy 2. Pathophysiology 3. Indications for Use 4. Adverse Effects 5. How Patients Access
Medical Marijuana Deb Evans, RN, MScN, CON(C), CHPCN(C) Clinical Nurse Specialist Pain and Symptom Management Team Juravinski Cancer Centre May 29, 2014 Objectives 1. Review controversy 2. Pathophysiology
More informationA Primer About Cannabidiol And The Benefits of CBD
A Primer About Cannabidiol And The Benefits of CBD Scientists are rapidly discovering more and more about the rather amazing abilities of the cannabinoids found in the cannabis plant. Most of them have
More informationDurban Poison (Pure Indica) Hindu Kush (Pure Sativa) Northern Lights (Ruderalis-Indica Hybrid) Royal Dwarf (Ruderalis-Sativa Hybrid) 11 Adapted from Figure 1. The endocannabinoid System in the Nervous
More informationMEDICAL MARIJUANA: WHAT S THE EVIDENCE?
MEDICAL MARIJUANA: WHAT S THE EVIDENCE? L A U R A A. M A R K L E Y, M D B O A R D - C E R T I F I E D I N P E D I A T R I C S / G E N E R A L P S Y C H I A T R Y / C H I L D & A D O L E S C E N T P S Y
More informationJuly 15 TH, ANDREW MEDVEDOVSKY, M.D. Board Certified Neurologist & Pain Medicine Specialist Director New Jersey Alternative Medicine
MEDICAL CANNABIS FOR NEUROLOGICAL DISEASES July 15 TH, 2017 ANDREW MEDVEDOVSKY, M.D. Board Certified Neurologist & Pain Medicine Specialist Director New Jersey Alternative Medicine GOALS AND OBJECTIVES
More informationCannabis: Rocky Mountain Highlights for Health Care Providers
Cannabis: Rocky Mountain Highlights for Health Care Providers HASHing It Out: Overview of Medical Uses for Marijuana Skaggs School of Pharmacy Webinar Series Laura Borgelt, PharmD, FCCP, BCPS Associate
More informationThe Return of Medicinal Cannabis
The Return of Medicinal Cannabis George Kolodner, M.D. DLFAPA FASAM Chief Clinical Officer Clinical Professor of Psychiatry Georgetown University School of Medicine University of Maryland School of Medicine
More informationNew potential therapeutic applications for certain phytocannabinoids revealed by pharmacological discoveries Roger Pertwee
New potential therapeutic applications for certain phytocannabinoids revealed by pharmacological discoveries Roger Pertwee UNIVERSITY OF ABERDEEN Cannabis - a unique source of phytocannabinoids (at least
More informationCannabinoids: access and symptom management in cancer
Cannabinoids: access and symptom management in cancer Appetite stimulation Anecdotal reports suggest marijuana stimulates appetite AIDS/HIV dronabinol 2.5 mg bd v placebo (n=88) increase in appetite 38%
More informationFrom Opioid Replacement to Managing Chronic Pain: What is CBD?
From Opioid Replacement to Managing Chronic Pain: What is CBD? Kalev Freeman, MD PhD Assistant Professor of Surgery and Pharmacology, University of Vermont Laura Mann Integrative Healthcare Lecture Series
More informationMarijuana and cannabinoids
Psych 181: Dr. Anagnostaras Lec 10: Marijuana Marijuana and cannabinoids Cannabis sativa, hemp One of earliest non-food plants cultivated fiber for rope, seeds for oil and birdseed 1st archaeological evidence
More informationAcknowledgements: What it is What it s not. Cannabis Evidence Series. Evidence-informed decision-making
Cannabis Evidence Series What it is What it s not Acknowledgements: The evidence presented is from the Cannabis evidence series authored by the HTA unit at the University of Calgary and from Rapid response
More informationMedical Cannabis: A Patient Primer
Medical Cannabis: A Patient Primer This primer is meant for documented patients who are using medicinal cannabis or considering using it in the future. The information provided about this medication in
More informationMedical vs Recreational Use of Cannabis. 11 th December 2017
1 Medical vs Recreational Use of Cannabis 11 th December 2017 2 Defining Cannabis and Chemical Constituents Cannabis is a plant species. Two main Cannabis sub-species are Cannabis Sativa and Cannabis Indica.
More informationRequirement for Certification from a Health Care Practitioner. Requirement for Certification from a Health Care Practitioner
Johnson County Pharmacists Association Current Status of the Iowa Ronald A. Herman, Ph.D. 1 Objectives Identify the current status of Iowa medical cannabis regulations. List the current disease conditions
More informationCell body, axon, dendrite, synapse
SOME BASIC NEUROSCIENCE Neurons have specialised extensions 1: Label the parts of a neuron by selecting the correct term from the box below. Cell body, axon, dendrite, synapse 1 dendrite synapse cell body
More information9/13/2017. Marijuana and the Brain Matthew Wong, MD Assistant Professor, Department of Neurology, Epilepsy Section. Disclosures.
Marijuana and the Brain Matthew Wong, MD Assistant Professor, Department of Neurology, Epilepsy Section Disclosures Site principal investigator of studies of cannabidiol(epidiolex) in the treatment of
More informationWHO Expert Committee on Drug Dependence Pre-Review: Cannabis plant and resin. Expert Peer Review 2
WHO Expert Committee on Drug Dependence Pre-Review: Cannabis plant and resin Expert Peer Review 2 1. Comments based on the review report a. Evidence on dependence and abuse potential Dependence potential:
More informationSlide 1 Is Marijuana Medicine?
Slide 1 Is Marijuana Medicine? Perspectives, Potentials, & Problems Allan Barger, MSW PRI Research Analyst www.primeforlife.org Slide 2 Presentation Goals Define terms Identify and explain the human endocannabinoid
More informationFaculty/Presenter Disclosure
Faculty/Presenter Disclosure Faculty: Philippe Lucas Relationships with commercial interests: Philippe Lucas is a Research Affilliate with the Centre for Addictions Research of BC, as well as VP, Patient
More informationMedical Marijuana Consent Form
Medical Marijuana Consent Form A qualified physician may not delegate the responsibility of obtaining written informed consent to another person. The qualified patient or the patient s parent or legal
More informationMarijuana as Medicine
Marijuana as Medicine What is medical marijuana? The term medical marijuana refers to using the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness and other conditions.
More informationMEDICAL CANNABIS PATIENT COUNSELING. Krissy Bernazani, RPh Clinical Director Zen Leaf
MEDICAL CANNABIS PATIENT COUNSELING Krissy Bernazani, RPh Clinical Director Zen Leaf DISCLOSURE Krissy Bernazani is a paid employee of Freestate Wellness, dba Zen Leaf Maryland, a medical cannabis dispensary.
More informationGuidance for the use of. medicinal cannabis. in Australia. Patient information
Guidance for the use of medicinal cannabis in Australia Patient information Version 1, December 2017 Copyright Commonwealth of Australia 2017 This work is copyright. You may reproduce the whole or part
More informationMedical Cannabinoids for the Management of Chronic Noncancer Pain
Medical Cannabinoids for the Management of Chronic Noncancer Pain Dr Mark A. Ware MBBS MSc McGill University 12 June 2018 Disclosures Grants: CanniMed Consulting: CHI Inc Emmes 1 Canadian Consortium for
More informationSusan Allen-Evenson Hosts: Laura Lagano, MS, RDN, CDN Prepare for the Next Level: Incorporating Holistic Cannabis in the Nutrition Practice
Susan Allen-Evenson Hosts: Laura Lagano, MS, RDN, CDN Prepare for the Next Level: Incorporating Holistic Cannabis in the Nutrition Practice Integrative Clinical Nutritionist, Laura Lagano MS, RDN, CDN
More informationCannabis: Therapeutic properties of the plant
Cannabis: Therapeutic properties of the plant Medicinal cannabis is still illegal to be used in South Africa. In a victory for marijuana users across South Africa, ConCourt has officially legalised cannabis
More informationCannabis & Hemp therapeutic solutions
Cannabis & Hemp therapeutic solutions with Our Cannabis & Hemp quality standards Thanks to their rich characterization and proprietary extraction method, our therapeutic solutions are a reference point
More information2018/05/01 DISCLOSURE EFFECTS OF CANNABIS USE IN ADOLESCENTS
DISCLOSURE EFFECTS OF CANNABIS USE IN ADOLESCENTS No conflict of interest to declare No pharmaceutical industry support No support from cannabis producers Selene Etches MD, FRCPC Cannabis is the most widely
More informationCannabinoids in Medicine An Option? Psychiatric Diseases
Swiss Task Force for Cannabinoids in Medicine, STCM Bern, January 22 nd, 2013 Cannabinoids in Medicine An Option? Psychiatric Diseases S S A M Dr. med. Robert Hämmig Psychiatrie & Psychotherapie FMH Präsident
More informationThis is a duplicated text of a letter from GW Pharma Ltd. Contact the company for a copy of any references, attachments or enclosures.
Health Canada posts safety alerts, public health advisories, press releases and other notices from industry as a service to health professionals, consumers and other interested parties. Although Health
More informationMedicinal Cannabis. Patient Log Book. Record your cannabis use and find the right dose
Medicinal Cannabis Patient Log Book Record your cannabis use and find the right dose 1 Introduction A federal system is in place for medicinal cannabis that is distinct from recreational sales. To get
More informationMedical Marijuana. Speaker Disclosure Requirements. Share with a Partner 4/10/2015
Medical Marijuana Kent W. Peterson, MD, FACOEM Occupational Health Strategies, Inc. Charlottesville, VA Speaker Disclosure Requirements 1. Do not dispense, prescribe, refer or recommend MMJ 2. Have no
More informationLegalized Marijuana: Uses, Misuses & Abuses. Disclosures. Objectives. Kennon Heard University of Colorado SOM Dept Of Emergency Medicine
Legalized Marijuana: Uses, Misuses & Abuses Kennon Heard University of Colorado SOM Dept Of Emergency Medicine Disclosures Research grants McNeil Consumer Healthcare (Acetaminophen) Rare Disease Therapeutics
More informationCBD Oil: Benefits, Top Products, Where To Buy, And More
CBD Oil: Benefits, Top Products, Where To Buy, And More CBD hemp oil has a huge range of potential health benefits and uses, including reducing pain, soothing anxiety, fighting cancer, improving mood,
More informationPAST, PRESENT AND FUTURE OF MEDICAL CANNABIS
PAST, PRESENT AND FUTURE OF MEDICAL CANNABIS Asare B. Christian, MD, MPH Associate Outpatient Medical Director, Good Shepherd Rehabilitation Network Clinical Faculty, Penn Medicine Outline Medical History
More informationMedical Cannabis MATT WEBSTER DO, MS
Medical Cannabis MATT WEBSTER DO, MS Cannabis Sativa One of the oldest used drugs and medicinal remedies Most commonly abused illicit drug in the US There has been increasing access for medicinal MJ use
More informationGetting Into the Weed: Potentials and Pitfalls Affecting Medical Use
Getting Into the Weed: Potentials and Pitfalls Affecting Medical Use Cydney E. McQueen, PharmD Clinical Associate Professor UMKC School of Pharmacy Objectives Describe in simple terms the endocannabinoid
More informationCANNABIS AND CANADA S CHILDREN AND YOUTH CPS Podcast
CANNABIS AND CANADA S CHILDREN AND YOUTH CPS Podcast Developed by KEON MA and Dr. CHRISTINA GRANT for PedsCases.com July 6, 2018 INTRODUCTION: Keon: On June 21, 2018, Bill C-45, also known as the Cannabis
More informationMedical Marijuana. Navigating Medical Marijuana in Workers Compensation
Medical Marijuana Navigating Medical Marijuana in Workers Compensation Agenda Federal and State Laws Public Health Adverse Effects & Concerns Clinical Use Implications for Employers Implications for Workers
More informationCannabis Use: Scope of the Issue
Three Areas of Focus How Changing Cannabis Policy Will Affect Your Practice Kevin P. Hill, MD, MHS Director, McLean Hospital Division of Alcohol and Drug Abuse Belmont, MA Assistant Professor of Psychiatry,
More informationMedical Marihuana for Patients in the Lymphoma Setting. Speakers: Ruth Turner, RN, Con Rob Laister, PhD
Medical Marihuana for Patients in the Lymphoma Setting Speakers: Ruth Turner, RN, Con Rob Laister, PhD Medical Marihuana for Patients in the Lymhoma Setting Disclosure: No endorsement or promotion of marihuana
More informationClinical Education Initiative MEDICAL MARIJUANA 101. Speaker: Patricia Reed, PharmD
Clinical Education Initiative Support@ceitraining.org MEDICAL MARIJUANA 101 Speaker: Patricia Reed, PharmD 8/2/2017 Medical Marijuana 101 [video transcript] 00:00:12 - So we'll get started. Disclosures
More informationThe Cannabinoids: Looking Back and Ahead
The Cannabinoids: Looking Back and Ahead Raphael Mechoulam Center on Cannabinoid Research, Hebrew University, Jerusalem ".modulating endocannabinoid activity may have therapeutic potential in almost all
More informationMedical Cannabis. Christine Yoshioka, NP
Medical Cannabis Christine Yoshioka, NP Objectives Brief history of Cannabis in cultures Review of the Endocanabinoid system Exogenous cannabis Medical research involving cannabis and federal restrictions
More informationMARIJUANA & THE EFFECTS ON THE BRAIN
MARIJUANA & THE EFFECTS ON THE BRAIN Sheryl Ryan, MD Professor of Pediatrics Chief, Division of Adolescent Medicine, Penn State Health Hershey Medical Center DISCLOSURES I have no relevant financial relationships
More informationMarijuana Science Update
Marijuana Science Update Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse ADVANCING ADDICTION SCIENCE NIDA CANNABIS SCIENCE RESEARCH AREAS EPIDEMIOLOGY: National and Local
More informationCANNABIS AND CANNABINOIDS: 2017 REPORT, U.S. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE
1 CANNABIS AND CANNABINOIDS: 2017 REPORT, U.S. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE The Health Effects of Cannabis and Cannabinoids. The Current State of Evidence and Recommendations
More informationCBD Oil: Anxiety Aid & Much More
CBD Oil: Anxiety Aid & Much More This often misunderstood hemp extract may be a health miracle for many. LISA TURNER NOV 1, 2017 betternutrition.com You ve probably heard of and wondered about CBD (cannabidiol),
More informationResearch Findings Relating to Cannabidiol (CBD) and its Influence on Inflammatory Bowel Disease and Irritable Bowel Syndrome - by Nurse Romy -
1 Research Findings Relating to Cannabidiol (CBD) and its Influence on Inflammatory Bowel Disease and Irritable Bowel Syndrome - by Nurse Romy - This article is based upon published scientific findings.
More information